All In Biotech

Drug Trial Radar · NCT04174898

MSC Infusion for Anti-aging and Regenerative Therapy

Human Mesenchymal Stem Cell (hMSC) Infusion for Anti-Aging and REGENerative Therapy

Last checked: Nov 20, 2026Latest source record: Nov 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 15, 2020

Primary completion

Apr 14, 2021

Study completion Apr 14, 2022

Sponsor

Lead sponsor
Landmark Medical Centre Sdn BhdAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
CytoMed Therapeutics Pte Ltd
First posted
Nov 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of human Mesenchymal Stem Cell (hMSC) infusion therapy, in preserving general wellness and ameliorating or reversing the effects of aging in our study population

Conditions

  • Aging Well
  • Regenerative Medicine

Interventions

  • human Mesenchymal Stem Cell (MSC) infusion therapyBiological

    Subjects will be infused with 100million human MSCs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate number of Participants with Treatment-Related Adverse EventsTime frame: 1 year
  2. Improvement in General Well-Being, as assessed by our 'Quality of Life' Questionnaire, adapted from SF36.Time frame: 1 year
  3. Change in inflammatory marker levelsTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Landmark Medical Centre Sdn Bhd

    Johor Bahru, Johor Darul Takzim, Malaysia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.